AstraZeneca Discontinues Phase III eVOLVE-Lung02 Trial of PD-1/CTLA-4 Bispecific Volrustomig After Interim Review Against Pembrolizumab

What the committee concluded

AstraZeneca's statement says the IDMC "concluded that the volrustomig combination was unlikely to meet either of the dual primary endpoints of progression-free survival (PFS) or overall survival (OS) in the primary analysis population of patients with PD-L1 negative tumours (<1%) versus the comparator arm." The company gave no hazard ratios, event counts or follow-up, and described the safety profile of volrustomig plus chemotherapy as consistent with the individual medicines. AstraZeneca said it will work with investigators to ensure continuity of care and appropriate follow-up for patients on the trial.

Susan Galbraith, executive vice president for oncology hematology R&D, said: "We initiated the eVOLVE-Lung02 trial aiming to improve the outcomes for patients whose lung cancers have lower PD-L1 expression and a less durable response to current immunotherapy regimens. While we are disappointed, we will learn from this trial and are determined to continue pioneering new medicines from our industry-leading pipeline in our quest to improve outcomes for patients with lung cancer."

An 895-patient design built around PD-L1-negative disease

The trial randomized patients 1:1 to 750 mg of intravenous volrustomig with chemotherapy every three weeks for four cycles, followed by volrustomig every three weeks, or to 200 mg of pembrolizumab with chemotherapy on the same schedule, followed by pembrolizumab until 24 months of treatment, progression or another discontinuation criterion. Enrollment required PD-L1 below 50%, and the statistical plan made the PD-L1-negative subgroup, below 1%, the primary analysis population, with the intent-to-treat group a secondary analysis. ClinicalTrials.gov lists the study as active, not recruiting, with 895 participants enrolled. The release does not name the PD-L1 assay or scoring method used to assign patients to the two strata.

Volrustomig, formerly MEDI5752, is designed to block PD-1 and CTLA-4 on the same T cell. AstraZeneca described the agent as under evaluation "as monotherapy and in combinations in several tumour types with high unmet need," and its lung cancer statement landed the same morning as the company's positive SAFFRON readout for Tagrisso plus Orpathys, a separate program.

A therapeutic-window question from Leerink

BioPharma Dive's Jonathan Gardner placed volrustomig among the experimental medicines AstraZeneca is counting on toward an $80 billion revenue target by 2030, and reported that in the drug's first-in-human study one-third of enrollees stopped treatment because of side effects. Analysts at Leerink Partners, he wrote, have questioned whether a "therapeutic window" exists in which the bispecific achieves enough tumor response without excess toxicity. Those points come from the trade outlet and an analyst note, not from AstraZeneca's release, which says nothing about discontinuation rates in eVOLVE-Lung02.

Why This Matters to the APO|APE Reader

Bristol Myers Squibb's Yervoy plus Opdivo and AstraZeneca's own Imfinzi plus Imjudo already pair CTLA-4 and PD-(L)1 blockade as two separate antibodies, and eVOLVE-Lung02 was the test of whether a single molecule doing both could displace pembrolizumab in the lowest-PD-L1 lung cancers, where the company itself said responses to current immunotherapy are least durable. The failed primary population was defined entirely by a PD-L1 score below 1%, so the result lands on the same tumor proportion score that labs already report for every new NSCLC, with no new assay in play. Cervical, head and neck and mesothelioma Phase IIIs now carry the molecule, and those will be judged partly on whether the toxicity burden that Leerink flagged in the first-in-human data reappears.